Chemistry:Iohexol

From HandWiki
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Short description: Chemical compound
Iohexol
Iohexol.svg
Clinical data
Trade namesOmnipaque, Hexopaque, Oraltag, others
Other names5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration		intrathecal, intravascular, by mouth, intracavital, rectal
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein bindingLow
MetabolismNil
Elimination half-lifeVariable
ExcretionKidney, unchanged
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC19H26I3N3O9
Molar mass821.142 g·mol−1
3D model (JSmol)
Melting point174 to 180 °C (345 to 356 °F)
 ☒N☑Y (what is this?)  (verify)

Iohexol, sold under the trade name Omnipaque among others, is a contrast agent used for X-ray imaging.[1] This includes when visualizing arteries, veins, ventricles of the brain, the urinary system, and joints, as well as during computed tomography (CT scan).[1] It is given by mouth, injection into a vein, or into a body cavity.[2]

Side effects include vomiting, skin flushing, headache, itchiness, kidney problems, and low blood pressure.[1] Less commonly allergic reactions or seizures may occur.[1] Allergies to povidone-iodine or shellfish do not affect the risk of side effects more than other allergies.[3] Use in the later part of pregnancy may cause hypothyroidism in the baby.[4] Iohexol is an iodinated non-ionic radiocontrast agent.[1] It is in the low osmolar family.[5]

Iohexol was approved for medical use in 1985.[6] It is on the World Health Organization's List of Essential Medicines.[7][2]

Chemistry

The osmolality of iohexol ranges from 322 mOsm/kg—approximately 1.1 times that of blood plasma—to 844 mOsm/kg, almost three times that of blood.[8] Despite this difference, iohexol is still considered a low-osmolality contrast agent; the osmolality of older agents, such as diatrizoate, may be more than twice as high.[9]

Adverse effects

The most common side effects after intravenous injections are: pain at the site of injection (3%), blurring of vision (2%), nausea (2%), arrhythmia (2%), taste perversion (1%), hypotension (0.7%), and vomiting (0.7%).[10]

Society and culture

Naming

It is sold under the brand names Omnipaque.[11] It is also sold as a density gradient medium under the names Accudenz, Histodenz, and Nycodenz.[12][13]

Available forms

It is available in various concentrations, from 140[10] to 350[14] milligrams of iodine per milliliter.[10] Iohexol can given as intrathecal, intravascular, oral, rectal, intraarticular, or into the body cavity.[10]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 WHO Model Formulary 2008. World Health Organization. 2009. pp. 317–8. ISBN 9789241547659. 
  2. ↑ 2.0 2.1 Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2015. p. 171. ISBN 9781284057560. 
  3. ↑ ACR Manual on Contrast Media v10.3. 2017. American College of Radiology. 2017. p. 6. ISBN 9781559030120. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Retrieved 1 January 2018. 
  4. ↑ (in en) Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. 2011. p. 761. ISBN 9781608317080. https://books.google.com/books?id=OIgTE4aynrMC&pg=PA761. 
  5. ↑ (in en) A Short Textbook of Clinical Imaging. Springer Science & Business Media. 2012. p. 235. ISBN 9781447117551. https://books.google.com/books?id=muflBwAAQBAJ&pg=PA235. 
  6. ↑ (in en) Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals. Springer Science & Business Media. 2013. p. 325. ISBN 9789401590884. https://books.google.com/books?id=tkPwCAAAQBAJ&pg=PA325. 
  7. ↑ World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO. 
  8. ↑ GE Healthcare (May 2006). "Omnipaque (Iohexol) injection. Product label". DailyMed. U.S. National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/fdaDrugXsl.cfm?id=3465&type=display. 
  9. ↑ Amersham Health (April 2006). "Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label". DailyMed. U.S. National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/fdaDrugXsl.cfm?id=997&type=display. 
  10. ↑ 10.0 10.1 10.2 10.3 "Highlights of prescribing information for Omnipaque". US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018956s101lbl.pdf. 
  11. ↑ "Omnipaque". Ireland: Health Products Regulatory Authority. January 2018. https://www.hpra.ie/img/uploaded/swedocuments/666c85d0-2222-42f9-873f-a269d151e198.pdf. 
  12. ↑ "HistoDenz". Product information sheet. Sigma-Aldrich. https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/d2158pis.pdf. 
  13. ↑ "Nycodenz®: A universal density gradient medium". Axis-Shield Density Gradient Media.. http://www.axis-shield-density-gradient-media.com/Leaflet%20Nycodenz.pdf. 
  14. ↑ (in German) Austria-Codex. Vienna: Österreichischer Apothekerverlag. 2020. Omnipaque 350 mg J/ml Infusionsflasche. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Iohexol&oldid=3329435"